BACKGROUND AND AIMS: Pioglitazone (PIO), a potent agonist of PPAR-gamma, is a promising candidate treatment for cocaine use disorder (CUD). We tested the effects of PIO on targeted mechanisms relevant to CUD: cocaine craving and brain white matter (WM) integrity. Feasibility, medication compliance and tolerability were evaluated. DESIGN: Two-arm double-blind randomized controlled proof-of-concept pilot trial of PIO or placebo (PLC). SETTING: Single-site out-patient treatment research clinic in Houston, TX, USA. PARTICIPANTS: Thirty treatment-seeking adults, 18 to 60 years old, with CUD. Eighteen participants (8 = PIO; 10 = PLC) completed diffusion tensor imaging (DTI) of WM integrity at pre-/post-treatment. INTERVENTION: Study medication was dispensed at thrice weekly visits along with once-weekly cognitive behavioral therapy for 12 weeks. MEASUREMENTS: Measures of target engagement mechanisms of interest included cocaine craving assessed by the Brief Substance Craving Scale (BSCS), the Obsessive Compulsive Drug Use Scale (OCDUS), a visual analog scale (VAS) and change in WM integrity. Feasibility measures included number completing treatment, medication compliance (riboflavin detection) and tolerability (side effects, serious adverse events). FINDINGS: Target engagement change in mechanisms of interest, defined as a ≥ 0.75 Bayesian posterior probability of an interaction existing favoring PIO over PLC, was demonstrated on measures of craving (BSCS, VAS) and WM integrity indexed by fractional anisotropy (FA) values. Outcomes indicated greater decrease in craving and greater increase in FA values in the PIO group. Feasibility was demonstrated by high completion rates among those starting treatment (21/26 = 80%) and medication compliance (≥ 80%). There were no reported serious adverse events for PIO. CONCLUSIONS: Compared with placebo, patients receiving pioglitazone show a higher likelihood of reduced cocaine craving and improved brain white matter integrity as a function of time in treatment. Pioglitazone shows good feasibility as a treatment for cocaine use disorder.
RCT Entities:
BACKGROUND AND AIMS: Pioglitazone (PIO), a potent agonist of PPAR-gamma, is a promising candidate treatment for cocaine use disorder (CUD). We tested the effects of PIO on targeted mechanisms relevant to CUD: cocaine craving and brain white matter (WM) integrity. Feasibility, medication compliance and tolerability were evaluated. DESIGN: Two-arm double-blind randomized controlled proof-of-concept pilot trial of PIO or placebo (PLC). SETTING: Single-site out-patient treatment research clinic in Houston, TX, USA. PARTICIPANTS: Thirty treatment-seeking adults, 18 to 60 years old, with CUD. Eighteen participants (8 = PIO; 10 = PLC) completed diffusion tensor imaging (DTI) of WM integrity at pre-/post-treatment. INTERVENTION: Study medication was dispensed at thrice weekly visits along with once-weekly cognitive behavioral therapy for 12 weeks. MEASUREMENTS: Measures of target engagement mechanisms of interest included cocaine craving assessed by the Brief Substance Craving Scale (BSCS), the Obsessive Compulsive Drug Use Scale (OCDUS), a visual analog scale (VAS) and change in WM integrity. Feasibility measures included number completing treatment, medication compliance (riboflavin detection) and tolerability (side effects, serious adverse events). FINDINGS: Target engagement change in mechanisms of interest, defined as a ≥ 0.75 Bayesian posterior probability of an interaction existing favoring PIO over PLC, was demonstrated on measures of craving (BSCS, VAS) and WM integrity indexed by fractional anisotropy (FA) values. Outcomes indicated greater decrease in craving and greater increase in FA values in the PIO group. Feasibility was demonstrated by high completion rates among those starting treatment (21/26 = 80%) and medication compliance (≥ 80%). There were no reported serious adverse events for PIO. CONCLUSIONS: Compared with placebo, patients receiving pioglitazone show a higher likelihood of reduced cocaine craving and improved brain white matter integrity as a function of time in treatment. Pioglitazone shows good feasibility as a treatment for cocaine use disorder.
Authors: Liangsuo Ma; Joel L Steinberg; Lori Keyser-Marcus; Divya Ramesh; Ponnada A Narayana; Randall E Merchant; F Gerard Moeller; David X Cifu Journal: Drug Alcohol Depend Date: 2015-03-23 Impact factor: 4.492
Authors: Ponnada A Narayana; Juan J Herrera; Kurt H Bockhorst; Emilio Esparza-Coss; Ying Xia; Joel L Steinberg; F Gerard Moeller Journal: Psychiatry Res Date: 2014-01-23 Impact factor: 3.222
Authors: Liliane Michalik; Johan Auwerx; Joel P Berger; V Krishna Chatterjee; Christopher K Glass; Frank J Gonzalez; Paul A Grimaldi; Takashi Kadowaki; Mitchell A Lazar; Stephen O'Rahilly; Colin N A Palmer; Jorge Plutzky; Janardan K Reddy; Bruce M Spiegelman; Bart Staels; Walter Wahli Journal: Pharmacol Rev Date: 2006-12 Impact factor: 25.468
Authors: Khader M Hasan; John A Lincoln; Flavia M Nelson; Jerry S Wolinsky; Ponnada A Narayana Journal: Magn Reson Imaging Date: 2014-12-05 Impact factor: 2.546
Authors: Kelvin O Lim; Jeffrey R Wozniak; Bryon A Mueller; Daniel T Franc; Sheila M Specker; Craig P Rodriguez; Amy B Silverman; John P Rotrosen Journal: Drug Alcohol Depend Date: 2007-09-29 Impact factor: 4.492
Authors: Bernard Le Foll; Patricia Di Ciano; Leigh V Panlilio; Steven R Goldberg; Roberto Ciccocioppo Journal: Curr Drug Targets Date: 2013-06 Impact factor: 3.465
Authors: Charles Green; Joy Schmitz; Jan Lindsay; Claudia Pedroza; Scott Lane; Rob Agnelli; Kimberley Kjome; F Gerard Moeller Journal: Front Psychiatry Date: 2012-10-30 Impact factor: 4.157
Authors: Charlotte L Beard; Joy M Schmitz; Heather E Soder; Robert Suchting; Jin H Yoon; Khader M Hasan; Ponnada A Narayana; F Gerard Moeller; Scott D Lane Journal: Drug Alcohol Depend Date: 2019-05-29 Impact factor: 4.492
Authors: Milky Kohno; Jeanne Link; Laura E Dennis; Holly McCready; Marilyn Huckans; William F Hoffman; Jennifer M Loftis Journal: Pharmacol Biochem Behav Date: 2019-01-26 Impact factor: 3.533
Authors: Joyce P Samuel; Jon E Tyson; Charles Green; Cynthia S Bell; Claudia Pedroza; Don Molony; Joshua Samuels Journal: Pediatrics Date: 2019-03-06 Impact factor: 7.124
Authors: Irma E Cisneros; Mert Erdenizmenli; Kathryn A Cunningham; Slobodan Paessler; Kelly T Dineley Journal: Neuropharmacology Date: 2018-03-23 Impact factor: 5.250
Authors: Andrea L Dimet; Irma E Cisneros; Robert G Fox; Sonja J Stutz; Noelle C Anastasio; Kathryn A Cunningham; Kelly T Dineley Journal: J Vis Exp Date: 2018-06-18 Impact factor: 1.355
Authors: Jennifer R Schroeder; Karran A Phillips; David H Epstein; Michelle L Jobes; Melody A Furnari; Ashley P Kennedy; Markus Heilig; Kenzie L Preston Journal: Psychopharmacology (Berl) Date: 2018-08-06 Impact factor: 4.530
Authors: Thomas F Northrup; Robert Suchting; Michelle R Klawans; Amir M Khan; Yolanda R Villarreal; Charles Green; Angela L Stotts Journal: J Neonatal Nurs Date: 2020-01-11